54,836 Shares in CVRx, Inc. (NASDAQ:CVRX) Purchased by Tradewinds LLC.

Tradewinds LLC. purchased a new stake in CVRx, Inc. (NASDAQ:CVRX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 54,836 shares of the company's stock, valued at approximately $695,000. Tradewinds LLC. owned 0.23% of CVRx as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Calamos Advisors LLC bought a new stake in CVRx during the 4th quarter valued at approximately $134,000. XTX Topco Ltd acquired a new position in shares of CVRx during the third quarter worth approximately $150,000. Jane Street Group LLC boosted its position in shares of CVRx by 36.1% in the third quarter. Jane Street Group LLC now owns 19,038 shares of the company's stock valued at $168,000 after acquiring an additional 5,053 shares during the period. Barclays PLC grew its stake in shares of CVRx by 312.5% in the third quarter. Barclays PLC now owns 19,067 shares of the company's stock worth $169,000 after acquiring an additional 14,445 shares during the last quarter. Finally, Centiva Capital LP acquired a new position in CVRx during the 3rd quarter valued at $178,000. Institutional investors own 75.27% of the company's stock.

CVRx Price Performance

NASDAQ:CVRX traded down $0.55 on Friday, reaching $11.72. The stock had a trading volume of 228,357 shares, compared to its average volume of 287,706. The company has a market capitalization of $305.14 million, a P/E ratio of -4.36 and a beta of 1.34. The stock has a fifty day moving average price of $13.48 and a 200-day moving average price of $12.97. The company has a quick ratio of 10.23, a current ratio of 12.06 and a debt-to-equity ratio of 0.69. CVRx, Inc. has a 1-year low of $6.40 and a 1-year high of $19.24.

CVRx (NASDAQ:CVRX - Get Free Report) last announced its earnings results on Tuesday, February 4th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%. Research analysts forecast that CVRx, Inc. will post -1.91 EPS for the current year.

Analyst Ratings Changes

CVRX has been the topic of several research analyst reports. William Blair upgraded shares of CVRx from a "market perform" rating to an "outperform" rating in a research report on Tuesday, January 14th. Craig Hallum boosted their price target on CVRx from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, January 17th. Canaccord Genuity Group raised their price objective on CVRx from $22.00 to $23.00 and gave the stock a "buy" rating in a research report on Wednesday, February 5th. Finally, Piper Sandler raised their target price on CVRx from $16.00 to $20.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 5th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.83.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.